SCHEMBL4912631

SCHEMBL4912631

COc1cccc(-c2nc(NC3CC3)nc(Cl)c2C#N)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA2A P29274 6/20 0.57
▸ ADORA1 P30542 6/20 0.57
▸ ADORA2B P29275 4/20 0.51
▸ BRAF P15056 1/20 0.50
▸ PDE4A P27815 1/20 0.50
▸ PDE4B Q07343 1/20 0.50
▸ PDE4C Q08493 1/20 0.50
▸ PDE4D Q08499 1/20 0.50
▸ MAPT P10636 2/20 0.49
▸ HPGD P15428 4/20 0.48
▸ MEN1 O00255 4/20 0.48
▸ KMT2A Q03164 4/20 0.48
▸ ALDH1A1 P00352 3/20 0.48
▸ POLB P06746 1/20 0.48
▸ RXFP1 Q9HBX9 1/20 0.47
▸ CTSL P07711 1/20 0.47
▸ CTSB P07858 1/20 0.47
▸ CTSS P25774 1/20 0.47
▸ CTSK P43235 1/20 0.47
▸ HTT P42858 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4908567 0.87 ADORA2A (0.57) ADORA2AADORA1ADORA2BBRAFPDE4A
SCHEMBL4907157 0.86 ADORA1 (0.46) ADORA2AADORA1ADORA2BBRAFPDE4A
SCHEMBL4908545 0.86 BRAF (0.49) ADORA2AADORA1ADORA2BBRAFPDE4A
SCHEMBL4909018 0.85 ADORA1 (0.56) ADORA2AADORA1ADORA2BCTSLCTSS
SCHEMBL4899380 0.84 ADORA1 (0.53) ADORA2AADORA1ADORA2BCTSLCTSS
SCHEMBL4906255 0.82 ADORA1 (0.47) ADORA2AADORA1ADORA2BHPGDMEN1
SCHEMBL4898198 0.82 HPGD (0.41) ADORA2AADORA1BRAFPDE4APDE4B
SCHEMBL4907249 0.80 KMT2A (0.41) ADORA2AADORA1ADORA2BBRAFPDE4A
SCHEMBL4898316 0.79 CTSL (0.50) ADORA2AADORA1BRAFPDE4DCTSL
SCHEMBL4906222 0.79 ALDH1A1 (0.45) ADORA2AADORA1PDE4BMAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1984377-A2 INHIBITORS OF TNF ALPHA , PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH Signal Pharmaceuticals LLC (US) 2008-10-29 — — EP disclosed
US-20080004271-A1 Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith MCKENNA JEFFREY M 2008-01-03 — — US disclosed
WO-2007084560-A2 INHIBITORS OF TNFα, PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH SIGNAL PHARMACEUTICALS, LLC (US) 2007-07-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004271-A1 Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith PDE4A, PDE4B, BRAF ADORA2A 837/4885ADORA1 529/4885ADORA2B 953/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback